SPOTLIGHT -
EP. 1: Work-Up and Management of Nondriver Metastatic Lung Cancer
EP. 2: Therapy Approach for PD-L1 Over 50% Lung Cancer
EP. 3: Progression on Immunotherapy: Treatment Approach
EP. 4: PD-L1 Less Than 49%: Available Treatments
EP. 5: Immunotherapy and Brain Metastatic Lung Cancer
EP. 6: How Long to Continue Immunotherapy
EP. 7: The IMpower150 Regimen
EP. 8: When to Use the CheckMate-227 Regimen
EP. 9: Lung Cancer Molecular Testing Protocol
EP. 10: Upfront Targeted Treatment Approach
EP. 11: Oligometastatic and Small Cell Transformation Management
EP. 12: When to Re-Treat with Osimertinib
EP. 13: ALK-Rearranged & MET Exon 14 NSCLC Treatment Options
EP. 14: Brain Metastatic NSCLC: Targeted Therapy Approach
EP. 15: Unresectable Stage III Lung Cancer Management
EP. 16: Stage III NSCLC: When to Start Durvalumab
EP. 17: Stage III NSCLC Progression Treatment Strategy
EP. 18: Small-Cell Lung Cancer: The IMpower133 and CASPIAN trials
EP. 19: Limited-Stage SCLC: Is Immunotherapy an Option?
EP. 20: The Future of Lung Cancer Management
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
